Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery

This study has been completed.
Biomet, Inc.
Information provided by (Responsible Party):
St. Louis Joint Replacement Institute Identifier:
First received: May 15, 2007
Last updated: April 26, 2016
Last verified: January 2010

This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day.

This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.

Condition Intervention Phase
Pain Management
Minimally Invasive Total Knee Arthroplasty
Drug: Celecoxib
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study

Resource links provided by NLM:

Further study details as provided by St. Louis Joint Replacement Institute:

Enrollment: 107
Study Start Date: June 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Sampling Method:   Probability Sample
Study Population
total knee canidates

Inclusion Criteria:

  • having undergone a minimally invasive total knee by select surgeon
  • voluntarily enrolled
  • independent community ambulators
  • only patients being discharged directly home

Exclusion Criteria:

  • celecoxib allergy or intolerence
  • Renal insufficiency (defined as serum creatine level >1.5 mg/dL or BUN level >22mg/dL
  • History of bleeding gastic or duodenal ulceration
  • New York Heart Association Class III or IV Congestive Heart Failure
  • Previous myocardial infarction or cerebralvascular event
  • Severe inflammatory bowel disease
  • Known coagulation abnormality or hepatic disease
  • Chronic coumadin administration
  • Refusal by primary or cardiac physician
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00474773

United States, Missouri
DePaul Health Center
St. Louis, Missouri, United States, 63044
Sponsors and Collaborators
St. Louis Joint Replacement Institute
Biomet, Inc.
Principal Investigator: William C Schroer, MD St. Louis Joint Replacement Institute
  More Information

Responsible Party: St. Louis Joint Replacement Institute Identifier: NCT00474773     History of Changes
Other Study ID Numbers: GA3190YM 
Study First Received: May 15, 2007
Last Updated: April 26, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on October 21, 2016